Pulmonary involvement Pulmonary involvement Total p
No (n=57) Yes (n=69)
Mean ± SD (median) Mean ± SD (median) Mean ± SD (median)
Age (months) (median) 48,1±72,79 (6) 96,74±81,51 (75) 74,73±81,11 (24) 10,000*
Duration of fever (median) (days) 1,94±1,16 (2) 3,21±2 (2) 2,67±1,8 (2) 10,000*
Duration of cough(median) (days)
3,06±1,98 (2,5)
3,85±2,41 (3)
3,64±2,32 (3)
10,230
Duration of hospitalization(median) (days)
7,86±3,2 (8)
9,62±3,99 (9)
8,83±3,74 (8,5)
10,004*
n (%) n (%) n (%)
Gender Female 22 (%38,6) 34 (%49,3) 56 (%44,4) 20,230
Male 35 (%61,4) 35 (%50,7) 70 (%55,6)
Household close contact No 19 (%33,3) 27 (%39,1) 46 (%36,5) 30,455
Yes 37 (%64,9) 42 (%60,9) 79 (%62,7)
Underlying condition No 40 (%70,2) 43 (%62,3) 83 (%65,9) -
Gastroesophageal reflux 1 (%1,8) 0 (%0) 1 (%0,8)
Hydronephrosis 1 (%1,8) 0 (%0) 1 (%0,8)
Prematurity 2 (%3,5) 1 (%1,4) 3 (%2,4)
Congenital heart disease 4 (%7) 2 (%2,9) 6 (%4,8)
Asthma 1 (%1,8) 4 (%5,8) 5 (%4)
Type-1 diabetes mellitus 3 (%5,3) 1 (%1,4) 4 (%3,2)
Metabolic diseases 1 (%1,8) 4 (%5,8) 5 (%4)
Congenital neutropenia 1 (%1,8) 1 (%1,4) 2 (%1,6)
Epilepsy 0 (%0) 2 (%2,9) 2 (%1,6)
Immune deficiency 1 (%1,8) 3 (%4,3) 4 (%3,2)
Chronic kidney disease 0 (%0) 2 (%2,9) 2 (%1,6)
Obesity 0 (%0) 2 (%2,9) 2 (%1,6)
Autism 1 (%1,8) 0 (%0) 1 (%0,8)
Down syndrome 0 (%0) 1 (%1,4) 1 (%0,8)
Acute lymphoblastic leukemia 0 (%0) 2 (%2,9) 2 (%1,6)
Mental retardation 0 (%0) 1 (%1,4) 1 (%0,8)
Cerebral palsy 1 (%1,8) 0 (%0) 1 (%0,8)
Underlying condition No 40 (%70,2) 43 (%62,3) 83 (%65,9) 40,461
Yes 17 (%29,8) 26 (%37,7) 43 (%34,1)
Symptoms Fever 35 (%61,4) 48 (%69,6) 83 (%65,9) 20,336
Cough 18 (%31,6) 48 (%69,6) 66 (%52,4) 40,000*
Runny nose 2 (%3,5) 4 (%5,8) 6 (%4,8) 50,435
Sorethroat 1 (%1,8) 3 (%4,3) 4 (%3,2) -
Myalgia 6 (%10,5) 15 (%21,7) 21 (%16,7) 40,150
Abdominal pain 1 (%1,8) 4 (%5,8) 5 (%4) -
Diarrhoea 9 (%15,8) 5 (%7,2) 14 (%11,1) 40,217
Shortness of breath 1 (%1,8) 22 (%31,9) 23 (%18,3) -
Favipiravir use No 55 (%96,5) 56 (%81,2) 111 (%88,1) 40,018*
Yes 2 (%3,5) 13 (%18,8) 15 (%11,9)
Azithromycin use No 49 (%86) 50 (%72,5) 99 (%78,6) 40,105
Yes 8 (%14) 19 (%27,5) 27 (%21,4)
Antibiotherapy No 19 (%33,3) 9 (%13) 28 (%22,2) -
Ampicillin-sulbactam 3 (%5,3) 2 (%2,9) 5 (%4)
Ampicillin+cefotaxime 12 (%21,1) 6 (%8,7) 18 (%14,3)
Ceftriaxone 15 (%26,3) 14 (%20,3) 29 (%23)
Cefotaxime 4 (%7) 7 (%10,1) 11 (%8,7)
Teicoplanin+piperacillin-tazobactam 1 (%1,8) 1 (%1,4) 2 (%1,6)
Teicoplanin+ceftriaxone 1 (%1,8) 24 (%34,8) 25 (%19,8)
Vancomycin+ceftriaxone 1 (%1,8) 4 (%5,8) 5 (%4)
Cefepime 1 (%1,8) 2 (%2,9) 3 (%2,4)
Type of delivery Spontaneous vaginal delivery 23 (%40,4) 42 (%60,9) 65 (%51,6) 20,022*
Cesarean delivery 34 (%59,6) 27 (%39,1) 61 (%48,4)
Non-invasive mechanical ventilation No 57 (%100) 59 (%85,5) 116 (%92,1) -
Yes 0 (%0) 10 (%14,5) 10 (%7,9)
Neutropenia No 42 (%73,7) 56 (%81,2) 98 (%77,8) 40,430
Yes 15 (%26,3) 13 (%18,8) 28 (%22,2)
Lymphopenia No 52 (%91,2) 49 (%71) 101 (%80,2) 40,009*
Yes 5 (%8,8) 20 (%29) 25 (%19,8)
Corticosteroid use No 57 (%100) 58 (%84,1) 115 (%91,3) -
Yes 0 (%0) 11 (%15,9) 11 (%8,7)
Low molecular–weight heparin use No 53 (%93) 52 (%75,4) 105 (%83,3) 40,016*
Yes 4 (%7) 17 (%24,6) 21 (%16,7)
Mortality No 56 (%98,2) 69 (%100) 125 (%99,2) -
Yes 1 (%1,8) 0 (%0) 1 (%0,8)